-
Canakinumab, sold
under the
brand name Ilaris, is a
medication for the
treatment of
systemic juvenile idiopathic arthritis,
active Still's disease, including...
-
Treatments may
include corticosteroids, ciclosporin, infliximab, or
canakinumab. The
disease was
identified in 1930. It
affects approximately 1 person...
-
pharmaceutical drug
canakinumab was conducted. In this study,
canakinumab was
effective in
patients with YAOS, and thus
clinical trial of
canakinumab may be warranted...
- are
under study for
treating gout,
including anakinra,
canakinumab, and rilonacept.
Canakinumab may
result in
better outcomes than a low dose of a glucocorticoid...
- 2020 FDA
approved Ilaris (
canakinumab) for the
treatment of AOSD, this is the
first FDA
approved treatment for AOSD.
Canakinumab is
another anti-IL1 drug...
-
adding anakinra to the
daily colchicine regimen has been successful.
Canakinumab, an anti-interleukin-1-beta
monoclonal antibody, has
likewise been shown...
-
target for
treatment of
diabetic retinopathy. However,
systemic using of
canakinumab did not have a
significant effect. The role of IL-1β in age-related macular...
-
therapeutic target, and
medications such as anakinra, rilonacept, and
canakinumab have
revolutionized the
treatment of
autoinflammatory diseases.[citation...
-
attacks start. (Examined in a 12-year-old patient).[citation needed]
Canakinumab is a long
acting monoclonal antibody which is
directed against IL-1β...
- as tocilizumab, and anti-interleukin-1 medications, such as anakinra,
canakinumab, or rilonacept, are
highly successful in
managing the disease's systemic...
